Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Zimmer Biomet logoZimmer Biomet ZBH

The company said its net sales for the 3- and 6-month periods ended June 30, 2024 rose 3.9% and 3.5%, respectively, from the same periods a year earlier. It said foreign currency exchange rates had a negative effect of 1.7% and 1.5%, respectively.

10-QQuarterly reportFiled Period of report Summary published (UTC)

Key points

AI summary
  1. The company said its net sales for the 3- and 6-month periods ended June 30, 2024 rose 3.9% and 3.5%, respectively, from the same periods a year earlier. It said foreign currency exchange rates had a negative effect of 1.7% and 1.5%, respectively.

  2. The company said net earnings were $242.8 million for the three-month period and $415.2 million for the six-month period, compared with $209.6 million and $442.1 million in the same prior year periods. It cited the 2023 Restructuring Plan costs, including $81.1 million in employee termination benefits-related charges, as the main factor behind the decline in earnings for the six-month period.

  3. The company said cash flows from operating activities were $597.4 million for the 6-month period ($655.6 million in the prior year). It said investing activities used $442.0 million and financing activities used $142.0 million. In financing, it borrowed a net $115.0 million under its Uncommitted Credit Facility and used that money, along with cash on hand, to repurchase $199.5 million of its common stock.

  4. The company said total debt was $5,834.7 million as of June 30, 2024, of which $1,878.0 million was classified as current debt. The company said that May 2024 it authorized a $2.0 billion share repurchase program, and that the amount remaining under the program as of June 30 was $1,904.6 million.

Key figures

Quarter ended June 30, 2024

Revenue
$1.9B
Operating income
$351M
Net income
$243M
EPS
$1.18

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Quarterly and Six-Month Net Sales Growth and Currency Impact

The company said its net sales for the 3- and 6-month periods ended June 30, 2024 rose 3.9% and 3.5%, respectively, from the same periods a year earlier. It said foreign currency exchange rates had a negative effect of 1.7% and 1.5%, respectively.

Source · Based on the MD&A text of the filing

Net Earnings Changes and 2023 Restructuring Plan

The company said net earnings were $242.8 million for the three-month period and $415.2 million for the six-month period, compared with $209.6 million and $442.1 million in the same prior year periods. It cited the 2023 Restructuring Plan costs, including $81.1 million in employee termination benefits-related charges, as the main factor behind the decline in earnings for the six-month period.

Source · Based on the MD&A text of the filing

6-Month Cash Flows and Share Repurchases

The company said cash flows from operating activities were $597.4 million for the 6-month period ($655.6 million in the prior year). It said investing activities used $442.0 million and financing activities used $142.0 million. In financing, it borrowed a net $115.0 million under its Uncommitted Credit Facility and used that money, along with cash on hand, to repurchase $199.5 million of its common stock.

Source · Based on the MD&A text of the filing

Debt Balance and New Share Repurchase Program

The company said total debt was $5,834.7 million as of June 30, 2024, of which $1,878.0 million was classified as current debt. The company said that May 2024 it authorized a $2.0 billion share repurchase program, and that the amount remaining under the program as of June 30 was $1,904.6 million.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.